search
Back to results

Assessment of 3M Oedema Reduction System in the Treatment of Lymphoedema Compared to Commercial Short-stretch Bandage

Primary Purpose

Lymphedema

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
3M Coban 2 (Compression System)
3M Coban 2 (Compression System)
3M Coban 2 (Compression System)
Comprilan
Sponsored by
3M
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lymphedema focused on measuring lymphoedema, lymphedema

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria (Arm):

  • Mobile males or females, age 18 years or older
  • Unilateral arm lymphoedema of secondary origin
  • Pitting arm lymphoedema diagnosed as stage II or late stage II according to the International Society of Lymphology staging
  • Patients who require intense bandaging therapy (approx. >= 15% increase in arm volume over the opposite healthy arm)
  • Completion of all primary and adjuvant cancer treatments (surgery, chemotherapy, radiotherapy) at least 6 months prior to randomisation
  • Willing to give written informed consent and willing to comply with the study protocol

Inclusion Criteria (Leg):

  • Mobile males or females, age 18 years or older
  • Unilateral or bilateral leg lymphoedema of primary or secondary origin
  • Pitting leg lymphoedema diagnosed as stage II or late stage II according to the International Society of Lymphology staging
  • Patients who require intense bandaging therapy
  • Completion of all primary and adjuvant cancer treatments (surgery, chemotherapy, radiotherapy) at least 6 months prior to randomisation
  • Willing to give written informed consent and willing to comply with the study protocol

Exclusion Criteria (Arm):

  • Known pregnancy
  • Evidence of active cancer, either local or metastatic
  • A period of intense daily bandaging within the last month
  • Decompensated heart failure or clinically relevant kidney or liver disease
  • Known relevant arterial disease of the arms
  • Deep vein thrombosis or phlebitis in the last 3 months
  • Paralysis of the arms
  • Clinical infection of the arms (e.g. erysipelas)
  • Wounds located at the study arm that require dressing change more than once a week
  • History of allergic reactions to study material
  • Participation in any prospective clinical study that can potentially interfere with this study
  • Participants who are, in the opinion of the clinical investigator, unsuitable for enrolment in this study, for reasons not specified in the exclusion criteria.

Exclusion Criteria (Leg):

  • Known pregnancy
  • Evidence of active cancer, either local or metastatic
  • A period of intense daily bandaging within the last month
  • Decompensated heart failure or clinically relevant kidney or liver disease
  • Deep vein thrombosis or phlebitis in the last 3 months
  • Known relevant arterial disease of the legs
  • Paralysis of the legs
  • Clinical infection of the legs (e.g. erysipelas)
  • Circumferential Lymphorrhoea
  • Wounds located at the study leg that require dressing change more than once a week
  • History of allergic reactions to study material
  • Participation in any prospective clinical study that can potentially interfere with this study
  • Participants who are, in the opinion of the clinical investigator, unsuitable for enrolment in this study, for reasons not specified in the exclusion criteria.

Sites / Locations

  • NorthShore University Healthsystem
  • University of Missouri
  • University of Pennsylvania
  • Memorial Hermann Hyperbaric Center
  • 56 London Road Clinic
  • Kendal Lymphology Centre
  • LOROS Hospice
  • St Giles Hospice Lymphoedema Service
  • Enfield Macmillan Lymphoedema Service
  • St Oswalds Hospice Lymphoedema Clinic
  • Swansea Lymphoedema Service Singleton Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

Arm 1 - 3M Coban 2

Arm 2 - 3M Coban 2

Arm 3 - 3M Coban 2

Arm 4 - Comprilan

Arm Description

3M Coban 2 - 2 apps/wk

3M Coban 2 - 3 apps/wk

Arm 3 - 3M Coban 2 - 5 apps/wk

Comprilan short-stretch bandage 5 apps/wk

Outcomes

Primary Outcome Measures

Percent Volume Change of Affected Limb at End of Treatment Compared to Baseline.

Secondary Outcome Measures

Assessment of Safety by Incidence of Adverse Events.

Full Information

First Posted
March 22, 2010
Last Updated
October 10, 2018
Sponsor
3M
search

1. Study Identification

Unique Protocol Identification Number
NCT01096589
Brief Title
Assessment of 3M Oedema Reduction System in the Treatment of Lymphoedema Compared to Commercial Short-stretch Bandage
Official Title
Preliminary Study to Assess the Effectiveness of 3M Oedema Reduction System in the Treatment of Lymphoedema Treatment Compared to Comprilan Short-stretch Bandage Compression Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
October 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
3M

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Objectives. The primary objective of the study is to assess volume reduction in the treatment of lymphoedematous legs and arms with compression bandaging. Secondary objectives: Assessment of safety Quality of life Health economic parameters Slippage Subbandage pressure

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphedema
Keywords
lymphoedema, lymphedema

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
82 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm 1 - 3M Coban 2
Arm Type
Experimental
Arm Description
3M Coban 2 - 2 apps/wk
Arm Title
Arm 2 - 3M Coban 2
Arm Type
Experimental
Arm Description
3M Coban 2 - 3 apps/wk
Arm Title
Arm 3 - 3M Coban 2
Arm Type
Experimental
Arm Description
Arm 3 - 3M Coban 2 - 5 apps/wk
Arm Title
Arm 4 - Comprilan
Arm Type
Active Comparator
Arm Description
Comprilan short-stretch bandage 5 apps/wk
Intervention Type
Device
Intervention Name(s)
3M Coban 2 (Compression System)
Intervention Description
Nonwoven cohesive backing and foam.
Intervention Type
Device
Intervention Name(s)
3M Coban 2 (Compression System)
Intervention Description
Nonwoven cohesive backing and foam.
Intervention Type
Device
Intervention Name(s)
3M Coban 2 (Compression System)
Intervention Description
Nonwoven cohesive backing and foam.
Intervention Type
Device
Intervention Name(s)
Comprilan
Intervention Description
Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).
Primary Outcome Measure Information:
Title
Percent Volume Change of Affected Limb at End of Treatment Compared to Baseline.
Time Frame
baseline and after 3 weeks of treatment
Secondary Outcome Measure Information:
Title
Assessment of Safety by Incidence of Adverse Events.
Time Frame
3 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria (Arm): Mobile males or females, age 18 years or older Unilateral arm lymphoedema of secondary origin Pitting arm lymphoedema diagnosed as stage II or late stage II according to the International Society of Lymphology staging Patients who require intense bandaging therapy (approx. >= 15% increase in arm volume over the opposite healthy arm) Completion of all primary and adjuvant cancer treatments (surgery, chemotherapy, radiotherapy) at least 6 months prior to randomisation Willing to give written informed consent and willing to comply with the study protocol Inclusion Criteria (Leg): Mobile males or females, age 18 years or older Unilateral or bilateral leg lymphoedema of primary or secondary origin Pitting leg lymphoedema diagnosed as stage II or late stage II according to the International Society of Lymphology staging Patients who require intense bandaging therapy Completion of all primary and adjuvant cancer treatments (surgery, chemotherapy, radiotherapy) at least 6 months prior to randomisation Willing to give written informed consent and willing to comply with the study protocol Exclusion Criteria (Arm): Known pregnancy Evidence of active cancer, either local or metastatic A period of intense daily bandaging within the last month Decompensated heart failure or clinically relevant kidney or liver disease Known relevant arterial disease of the arms Deep vein thrombosis or phlebitis in the last 3 months Paralysis of the arms Clinical infection of the arms (e.g. erysipelas) Wounds located at the study arm that require dressing change more than once a week History of allergic reactions to study material Participation in any prospective clinical study that can potentially interfere with this study Participants who are, in the opinion of the clinical investigator, unsuitable for enrolment in this study, for reasons not specified in the exclusion criteria. Exclusion Criteria (Leg): Known pregnancy Evidence of active cancer, either local or metastatic A period of intense daily bandaging within the last month Decompensated heart failure or clinically relevant kidney or liver disease Deep vein thrombosis or phlebitis in the last 3 months Known relevant arterial disease of the legs Paralysis of the legs Clinical infection of the legs (e.g. erysipelas) Circumferential Lymphorrhoea Wounds located at the study leg that require dressing change more than once a week History of allergic reactions to study material Participation in any prospective clinical study that can potentially interfere with this study Participants who are, in the opinion of the clinical investigator, unsuitable for enrolment in this study, for reasons not specified in the exclusion criteria.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christine Moffatt, Prof.
Organizational Affiliation
Faculty of Medicine, Division of Nursing and Healthcare, Universtity of Glasgow, G12 8LW
Official's Role
Principal Investigator
Facility Information:
Facility Name
NorthShore University Healthsystem
City
Evanston
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Facility Name
University of Missouri
City
Columbia
State/Province
Missouri
ZIP/Postal Code
65203
Country
United States
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Memorial Hermann Hyperbaric Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
56 London Road Clinic
City
Milborne Port
State/Province
Dorset
ZIP/Postal Code
DT9 5DW
Country
United Kingdom
Facility Name
Kendal Lymphology Centre
City
Kendal
ZIP/Postal Code
LA9 4BD
Country
United Kingdom
Facility Name
LOROS Hospice
City
Leicester
ZIP/Postal Code
LE3 9QE
Country
United Kingdom
Facility Name
St Giles Hospice Lymphoedema Service
City
Lichfield
ZIP/Postal Code
WS14 9LH
Country
United Kingdom
Facility Name
Enfield Macmillan Lymphoedema Service
City
London
ZIP/Postal Code
N9 7HD
Country
United Kingdom
Facility Name
St Oswalds Hospice Lymphoedema Clinic
City
Newcastle-upon-Tyne
ZIP/Postal Code
NE3 1EE
Country
United Kingdom
Facility Name
Swansea Lymphoedema Service Singleton Hospital
City
Swansea
ZIP/Postal Code
SA2 8QA
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Assessment of 3M Oedema Reduction System in the Treatment of Lymphoedema Compared to Commercial Short-stretch Bandage

We'll reach out to this number within 24 hrs